BIOMAT Database Logo BIOMAT Database Logo

[Myasthenia gravis caused by D-penicillamine]. 1996

P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
[A case of myasthenia gravis caused by D-penicillamine therapy].
December 1998, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
[Myasthenia gravis induced by D-penicillamine].
August 1983, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
D-Penicillamine induced myasthenia gravis.
October 2002, Neurosciences (Riyadh, Saudi Arabia),
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
Myasthenia gravis and D-penicillamine.
January 1981, The Journal of rheumatology. Supplement,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
[D-penicillamine-induced myasthenia gravis].
January 1984, Duodecim; laaketieteellinen aikakauskirja,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
[D-penicillamine-induced myasthenia gravis].
May 1994, Schweizerische medizinische Wochenschrift,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
Ocular myasthenia gravis after D-penicillamine administration.
December 1989, The British journal of ophthalmology,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
[Myasthenia caused by D-penicillamine in rheumatoid arthritis].
January 1994, Revue du rhumatisme (Ed. francaise : 1993),
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
[Ocular myasthenia caused by D-penicillamine (author's transl)].
March 1976, Klinische Monatsblatter fur Augenheilkunde,
P J Sanz Gallego, and F C Pérez Sánchez, and A López Vázquez, and D Salgado Palacio
D-Penicillamine-induced myasthenia gravis in rheumatoid arthritis.
November 1977, Annals of internal medicine,
Copied contents to your clipboard!